The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review

{ 'indexed': {'date-parts': [[2022, 3, 25]], 'date-time': '2022-03-25T20:30:42Z', 'timestamp': 1648240242587}, 'reference-count': 72, 'publisher': 'Springer Science and Business Media LLC', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2021, 12, 21]], 'date-time': '2021-12-21T00:00:00Z', 'timestamp': 1640044800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}, { 'start': { 'date-parts': [[2021, 12, 21]], 'date-time': '2021-12-21T00:00:00Z', 'timestamp': 1640044800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'short-container-title': ['J Antibiot'], 'published-print': {'date-parts': [[2022, 2]]}, 'DOI': '10.1038/s41429-021-00491-6', 'type': 'journal-article', 'created': { 'date-parts': [[2021, 12, 21]], 'date-time': '2021-12-21T04:29:21Z', 'timestamp': 1640060961000}, 'page': '60-71', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 2, 'title': ['The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review'], 'prefix': '10.1038', 'volume': '75', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-6510-6365', 'authenticated-orcid': False, 'given': 'Asiya Kamber', 'family': 'Zaidi', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-8339-1868', 'authenticated-orcid': False, 'given': 'Puya', 'family': 'Dehgani-Mobaraki', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2021, 12, 21]]}, 'reference': [ { 'key': '491_CR1', 'doi-asserted-by': 'publisher', 'first-page': 'w20242', 'DOI': '10.4414/smw.2020.20242.', 'volume': '150', 'author': 'R Gharebaghi', 'year': '2020', 'unstructured': 'Gharebaghi R, Heidary F. COVID-19 and Iran: swimming with hands tied! ' 'Swiss Med Wkly. 2020;150:w20242. https://doi.org/10.4414/smw.2020.20242.', 'journal-title': 'Swiss Med Wkly'}, { 'key': '491_CR2', 'doi-asserted-by': 'publisher', 'first-page': '13', 'DOI': '10.2183/pjab.87.13.', 'volume': '87', 'author': 'A Crump', 'year': '2011', 'unstructured': 'Crump A, Ōmura S. Ivermectin, ‘wonder drug’ from Japan: the human use ' 'perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:13–28. ' 'https://doi.org/10.2183/pjab.87.13.', 'journal-title': 'Proc Jpn Acad Ser B Phys Biol Sci'}, { 'key': '491_CR3', 'first-page': '325', 'volume': '15', 'author': 'LH Kircik', 'year': '2016', 'unstructured': 'Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 years of ' 'clinical experience with ivermectin: an overview of safety for an ' 'increasing number of indications. J Drugs Dermatol. 2016;15:325–32.', 'journal-title': 'J Drugs Dermatol'}, { 'key': '491_CR4', 'doi-asserted-by': 'publisher', 'first-page': '42', 'DOI': '10.1208/s12248-007-9000-9.', 'volume': '10', 'author': 'A Gonzalez Canga', 'year': '2008', 'unstructured': 'Gonzalez Canga A, et al. The pharmacokinetics and interactions of ' 'ivermectin in humans–a mini-review. AAPS J. 2008;10:42–6. ' 'https://doi.org/10.1208/s12248-007-9000-9.', 'journal-title': 'AAPS J'}, { 'key': '491_CR5', 'doi-asserted-by': 'publisher', 'first-page': '30', 'DOI': '10.9734/jammr/2020/v32i1030512', 'volume': '32', 'author': 'BS Kumar', 'year': '2020', 'unstructured': 'Kumar BS, Jeyaraman M, Jain R, Anudeep TC. A wonder drug in the arsenal ' 'against COVID—19: medication evidence from ivermectin. J Adv Med Med ' 'Res. 2020;32:30–7.', 'journal-title': 'J Adv Med Med Res.'}, { 'key': '491_CR6', 'doi-asserted-by': 'publisher', 'first-page': '267', 'DOI': '10.1016/j.tips.2013.03.004', 'volume': '34', 'author': 'N Novac', 'year': '2013', 'unstructured': 'Novac N. Challenges and opportunities of drug repositioning. Trends ' 'Pharm Sci. 2013;34:267–72.', 'journal-title': 'Trends Pharm Sci'}, { 'key': '491_CR7', 'unstructured': 'ClinicalTrials.gov [Internet]. Clinicaltrials.gov. 2021 [cited 10 ' 'November 2021]. Available from: https://clinicaltrials.gov/ct2/home Home ' '- ClinicalTrials.gov.'}, { 'key': '491_CR8', 'unstructured': 'Activ6study.org. Activ-6 study. Activ6study.org; 2021. ' 'https://activ6study.org/.'}, { 'key': '491_CR9', 'unstructured': 'Principletrial.org. Join the PRINCIPLE Trial. Principletrial.org.; 2021. ' 'https://www.principletrial.org/.'}, { 'key': '491_CR10', 'doi-asserted-by': 'publisher', 'first-page': '681', 'DOI': '10.1007/BF00637608', 'volume': '35', 'author': 'G Edwards', 'year': '1988', 'unstructured': 'Edwards G, Dingsdale A, Helsby N, Orme ML, Breckenridge AM. The relative ' 'systemic availability of ivermectin after administration as capsule, ' 'tablet, and oral solution. Eur J Clin Pharm. 1988;35:681–4.', 'journal-title': 'Eur J Clin Pharm'}, { 'key': '491_CR11', 'doi-asserted-by': 'publisher', 'first-page': '583', 'DOI': '10.1007/s40262-016-0467-3', 'volume': '56', 'author': 'L Verrest', 'year': '2017', 'unstructured': 'Verrest L, Dorlo TPC. Lack of clinical pharmacokinetic studies to ' 'optimize the treatment of neglected tropical diseases: a systematic ' 'review. Clin Pharmacokinet. 2017;56:583–606.', 'journal-title': 'Clin Pharmacokinet'}, { 'key': '491_CR12', 'doi-asserted-by': 'publisher', 'first-page': '607', 'DOI': '10.1007/BF00316107.', 'volume': '39', 'author': 'U Klotz', 'year': '1990', 'unstructured': 'Klotz U, Ogbuokiri JE, Okonkwo PO. Ivermectin binds avidly to plasma ' 'proteins. Eur J Clin Pharmacol 1990;39:607–8. ' 'https://doi.org/10.1007/BF00316107.', 'journal-title': 'Eur J Clin Pharmacol'}, { 'key': '491_CR13', 'doi-asserted-by': 'publisher', 'unstructured': 'Wu MA, Fossali T, et al. Hypoalbuminemia in COVID-19: assessing the ' 'hypothesis for underlying pulmonary capillary leakage. J Intern Med. ' '2021. https://doi.org/10.1111/joim.13208.', 'DOI': '10.1111/joim.13208'}, { 'key': '491_CR14', 'unstructured': 'World Health Organization. Application for inclusion of ivermectin on ' 'the WHO Model List of Essential Medicines (EML) and Model List of ' 'Essential Medicines for Children (EMLc). World Health Organization; ' '2016.'}, { 'key': '491_CR15', 'doi-asserted-by': 'publisher', 'first-page': '48', 'DOI': '10.1016/j.pt.2020.10.005', 'volume': '37', 'author': 'RJ Martin', 'year': '2021', 'unstructured': 'Martin RJ, Robertson AP, Choudhary S. Ivermectin: an anthelmintic, an ' 'insecticide, and much more. Trends Parasitol. 2021;37:48–64. ' 'https://doi.org/10.1016/j.pt.2020.10.005.', 'journal-title': 'Trends Parasitol.'}, { 'key': '491_CR16', 'doi-asserted-by': 'publisher', 'first-page': '382', 'DOI': '10.4269/ajtmh.17-0042.', 'volume': '98', 'author': 'RE Chandler', 'year': '2018', 'unstructured': 'Chandler RE. Serious neurological adverse events after ivermectin-do ' 'they occur beyond the indication of onchocerciasis? Am J Trop Med Hyg. ' '2018;98:382–8. https://doi.org/10.4269/ajtmh.17-0042.', 'journal-title': 'Am J Trop Med Hyg'}, { 'key': '491_CR17', 'doi-asserted-by': 'publisher', 'author': 'Q Wang', 'year': '2020', 'unstructured': 'Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and ' 'functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020. ' 'https://doi.org/10.1016/j.cell.2020.03.045.', 'journal-title': 'Cell', 'DOI': '10.1016/j.cell.2020.03.045.'}, { 'key': '491_CR18', 'doi-asserted-by': 'publisher', 'unstructured': 'Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the ' 'novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. ' '2020. https://doi.org/10.1016/j.chom.2020.02.001.', 'DOI': '10.1016/j.chom.2020.02.001'}, { 'key': '491_CR19', 'doi-asserted-by': 'publisher', 'first-page': '64', 'DOI': '10.1016/j.virol.2013.11.040', 'volume': '450–451', 'author': 'AM Mielech', 'year': '2014', 'unstructured': 'Mielech AM, Kilianski A, Baez-Santos YM, Mesecar AD, Baker SC. MERS-CoV ' 'papain-like protease has deISGylating and deubiquitinating activities. ' 'Virology. 2014;450–451:64–70.', 'journal-title': 'Virology.'}, { 'key': '491_CR20', 'unstructured': 'Lehigh.edu. BioS 353. Lehigh.edu; 2021. ' 'https://www.lehigh.edu/~jas0/V14.html.'}, { 'key': '491_CR21', 'doi-asserted-by': 'publisher', 'first-page': '3023', 'DOI': '10.21873/invivo.12134', 'volume': '34', 'author': 'S Lehrer', 'year': '2020', 'unstructured': 'Lehrer S, Rheinstein PH. Ivermectin docks to the SARS-CoV-2 spike ' 'receptor-binding domain attached to ACE2. In Vivo. 2020;34:3023–6. ' 'https://doi.org/10.21873/invivo.12134.', 'journal-title': 'In Vivo.'}, { 'key': '491_CR22', 'doi-asserted-by': 'publisher', 'first-page': '592908.', 'DOI': '10.3389/fmicb.2020.592908', 'volume': '11', 'author': 'AF Eweas', 'year': '2021', 'unstructured': 'Eweas AF, Alhossary AA, Abdel-Moneim AS. Molecular docking reveals ' 'ivermectin and remdesivir as potential repurposed drugs against ' 'SARS-CoV-2. Front Microbiol. 2021;11:592908. ' 'https://doi.org/10.3389/fmicb.2020.592908.', 'journal-title': 'Front Microbiol.'}, { 'key': '491_CR23', 'doi-asserted-by': 'publisher', 'unstructured': 'Choudhury A, Das NC, Patra R, Bhattacharya M, Ghosh P, Patra BC, et al. ' 'Exploring the binding efficacy of ivermectin against the key proteins of ' 'SARS-CoV-2 pathogenesis: an in silico approach. Future Virol. 2021. ' 'https://doi.org/10.2217/fvl-2020-0342.', 'DOI': '10.2217/fvl-2020-0342'}, { 'key': '491_CR24', 'doi-asserted-by': 'publisher', 'first-page': '2176', 'DOI': '10.1016/j.bbamcr.2011.03.019', 'volume': '1813', 'author': 'A Fulcher', 'year': '2011', 'unstructured': 'Fulcher A, Jans DA. Regulation of nucleocytoplasmic trafficking of viral ' 'proteins; an integral role in pathogenesis? Biochem Biophys Acta Mol ' 'Cell Res. 2011;1813:2176–90.', 'journal-title': 'Biochem Biophys Acta Mol Cell Res.'}, { 'key': '491_CR25', 'doi-asserted-by': 'publisher', 'first-page': '104760', 'DOI': '10.1016/j.antiviral.2020.104760', 'volume': '177', 'author': 'SNY Yang', 'year': '2020', 'unstructured': 'Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al. ' 'The broad spectrum antiviral ivermectin targets the host nuclear ' 'transport importin α/β1 heterodimer. Antivir Res. 2020;177:104760.', 'journal-title': 'Antivir Res.'}, { 'key': '491_CR26', 'doi-asserted-by': 'crossref', 'unstructured': 'Freedman JC. Chapter 4—Ionophores in planar lipid bilayers. In: ' 'Sperelakis N, editor. Cell physiology sourcebook. Essentials of membrane ' 'biophysics, 4th ed. London, UK; Waltham, MA, USA; San Diego, CA, USA: ' 'Academic Press; 2012. p. 61–6.', 'DOI': '10.1016/B978-0-12-387738-3.00004-4'}, { 'key': '491_CR27', 'doi-asserted-by': 'publisher', 'first-page': '1153', 'DOI': '10.1007/s00210-020-01902-5.', 'volume': '393', 'author': 'E Rizzo', 'year': '2020', 'unstructured': 'Rizzo E. Ivermectin, antiviral properties and COVID-19: a possible new ' 'mechanism of action. Naunyn Schmiedebergs Arch Pharm. 2020;393:1153–6. ' 'https://doi.org/10.1007/s00210-020-01902-5.', 'journal-title': 'Naunyn Schmiedebergs Arch Pharm'}, { 'key': '491_CR28', 'doi-asserted-by': 'publisher', 'unstructured': 'Dueñas-González A, Juárez-Rodríguez M. Ivermectin: potential repurposing ' 'of a versatile antiparasitic as a novel anticancer. In: Raymond C, ' 'Dalgleish A, editors. Repurposed drugs for cancer. IntechOpen; 2021. ' 'https://doi.org/10.5772/intechopen.99813.', 'DOI': '10.5772/intechopen.99813'}, { 'key': '491_CR29', 'doi-asserted-by': 'publisher', 'first-page': '3397', 'DOI': '10.3892/mmr.2017.8231.', 'volume': '17', 'author': 'G Dominguez‑Gomez', 'year': '2018', 'unstructured': 'Dominguez‑Gomez G, Chavez‑Blanco A, Medina‑Franco JL, Saldivar‑Gonzalez ' 'F, Flores‑Torrontegui Y, Juarez M, et al. Ivermectin as an inhibitor of ' 'cancer stem‑like cells. Mol Med Rep. 2018;17:3397–403. ' 'https://doi.org/10.3892/mmr.2017.8231.', 'journal-title': 'Mol Med Rep'}, { 'key': '491_CR30', 'doi-asserted-by': 'publisher', 'first-page': '593', 'DOI': '10.1038/s41429-020-0336-z.', 'volume': '73', 'author': 'F Heidary', 'year': '2020', 'unstructured': 'Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral ' 'effects to COVID-19 complementary regimen. J Antibiot. 2020;73:593–602. ' 'https://doi.org/10.1038/s41429-020-0336-z.', 'journal-title': 'J Antibiot'}, { 'key': '491_CR31', 'doi-asserted-by': 'publisher', 'first-page': '192', 'DOI': '10.1177/1087057110390360.', 'volume': '16', 'author': 'KM Wagstaff', 'year': '2011', 'unstructured': 'Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA. An AlphaScreen(R)-based ' 'assay for high-throughput screening for specific inhibitors of nuclear ' 'import. J Biomol Screen. 2011;16:192–200. ' 'https://doi.org/10.1177/1087057110390360.', 'journal-title': 'J Biomol Screen'}, { 'key': '491_CR32', 'doi-asserted-by': 'publisher', 'first-page': '110', 'DOI': '10.1016/j.virol.2014.10.013.', 'volume': '474', 'author': 'SM Bennett', 'year': '2015', 'unstructured': 'Bennett SM, Zhao L, Bosard C, Imperiale MJ. Role of a nuclear ' 'localization signal on the minor capsid proteins VP2 and VP3 in BKPyV ' 'nuclear entry. Virology. 2015;474:110–6. ' 'https://doi.org/10.1016/j.virol.2014.10.013.', 'journal-title': 'Virology'}, { 'key': '491_CR33', 'doi-asserted-by': 'publisher', 'unstructured': 'Raza S, Shahin F, Zhai W, et al. Ivermectin inhibits bovine herpesvirus ' '1 DNA polymerase nuclear import and interferes with viral replication. ' 'Microorganisms. 2020;8. https://doi.org/10.3390/microorganisms8030409.', 'DOI': '10.3390/microorganisms8030409'}, { 'key': '491_CR34', 'doi-asserted-by': 'publisher', 'unstructured': 'Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ' 'ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral ' 'Res. 2020;104787. https://doi.org/10.1016/j.antiviral.2020.104787.', 'DOI': '10.1016/j.antiviral.2020.104787'}, { 'key': '491_CR35', 'doi-asserted-by': 'publisher', 'unstructured': 'Arshad U, Pertinez H, Box H, et al. Prioritization of anti-SARS-Cov-2 ' 'drug repurposing opportunities based on plasma and target site ' 'concentrations derived from their established human pharmacokinetics. ' 'Clin Pharmacol Ther. 2020. https://doi.org/10.1002/cpt.1909.', 'DOI': '10.1002/cpt.1909'}, { 'key': '491_CR36', 'unstructured': 'Yagisawa M, Foster PJ, Hanaki H, Ōmura S. Global trends in clinical ' 'studies of ivermectin in COVID-19. Jpn J Antibiotics. 2021;44:74-1.'}, { 'key': '491_CR37', 'doi-asserted-by': 'publisher', 'unstructured': 'Swargiary A. Ivermectin as a promising RNA-dependent RNA polymerase ' 'inhibitor and a therapeutic drug against SARS-CoV2: evidence from in ' 'silico studies. Research Square; 2020. ' 'https://doi.org/10.21203/rs.3.rs-73308/v1.', 'DOI': '10.21203/rs.3.rs-73308/v1'}, { 'key': '491_CR38', 'doi-asserted-by': 'publisher', 'first-page': '155', 'DOI': '10.1038/s41579-020-00468-6.', 'volume': '19', 'author': 'P V’kovski', 'year': '2021', 'unstructured': 'V’kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and ' 'replication: implications for SARS-CoV-2. Nat Rev Microbiol. ' '2021;19:155–70. https://doi.org/10.1038/s41579-020-00468-6.', 'journal-title': 'Nat Rev Microbiol'}, { 'key': '491_CR39', 'doi-asserted-by': 'publisher', 'first-page': '9436', 'DOI': '10.1073/pnas.1508686112', 'volume': '112', 'author': 'Y Ma', 'year': '2015', 'unstructured': 'Ma Y, Wu L, Shaw N, Gao Y, Wang J, Sun Y, et al. Structural basis and ' 'functional analysis of the SARS coronavirus nsp14-nsp10 complex. Proc ' 'Natl Acad Sci USA. 2015;112:9436–41.', 'journal-title': 'Proc Natl Acad Sci USA'}, { 'key': '491_CR40', 'doi-asserted-by': 'publisher', 'first-page': '93', 'DOI': '10.1038/s42003-020-01577-x', 'volume': '4', 'author': 'V Mody', 'year': '2021', 'unstructured': 'Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert MCCJC, et al. ' 'Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as ' 'potential anti-SARS-CoV-2 agents. Commun Biol. 2021;4:93. ' 'https://doi.org/10.1038/s42003-020-01577-x.', 'journal-title': 'Commun Biol'}, { 'key': '491_CR41', 'doi-asserted-by': 'publisher', 'first-page': '7067', 'DOI': '10.1093/emboj/16.23.7067', 'volume': '16', 'author': 'T Sekimoto', 'year': '1997', 'unstructured': 'Sekimoto T, Imamoto N, Nakajima K, Hirano T, Yoneda Y. Extracellular ' 'signal-dependent nuclear import of Stat1 is mediated by nuclear ' 'pore-targeting complex formation with NPI-1, but not Rch1. EMBO J. ' '1997;16:7067–77.', 'journal-title': 'EMBO J'}, { 'key': '491_CR42', 'doi-asserted-by': 'publisher', 'unstructured': 'Konno Y, Kimura I, Uriu K, Fukushi M, Irie T, Koyanagi Y, et al. ' 'SARS-CoV-2 ORF3b is a potent interferon antagonist whose activity is ' 'further increased by a naturally occurring elongation variant. Cell Rep. ' '2020. https://doi.org/10.1016/j.celrep.2020.108185.', 'DOI': '10.1016/j.celrep.2020.108185'}, { 'key': '491_CR43', 'doi-asserted-by': 'publisher', 'unstructured': 'Yang D, Chu H, Hou Y, Chai Y, Shuai H, Lee AC-Y, et al. Attenuated ' 'interferon and pro-inflammatory response in SARSCoV-2-infected human ' 'dendritic cells is associated with viral antagonism of STAT1 ' 'phosphorylation. J Infect Dis. 2020. ' 'https://doi.org/10.1093/infdis/jiaa356.', 'DOI': '10.1093/infdis/jiaa356'}, { 'key': '491_CR44', 'doi-asserted-by': 'publisher', 'first-page': '3209', 'DOI': '10.1038/s41418-020-00633-7.', 'volume': '27', 'author': 'T Matsuyama', 'year': '2020', 'unstructured': 'Matsuyama T, Kubli SP, Yoshinaga SK, et al. An aberrant STAT pathway is ' 'central to COVID-19. Cell Death Differ. 2020;27:3209–25. ' 'https://doi.org/10.1038/s41418-020-00633-7.', 'journal-title': 'Cell Death Differ'}, { 'key': '491_CR45', 'doi-asserted-by': 'publisher', 'first-page': 'e0168170', 'DOI': '10.1371/journal.pone.0168170', 'volume': '11', 'author': 'C Seth', 'year': '2016', 'unstructured': 'Seth C, Mas C, Conod A, Mueller J, Siems K, Kuciak M, et al. LongLasting ' 'WNT-TCF response blocking and epigenetic modifying activities of ' 'withanolide f in human cancer cells. PLoS ONE. 2016;11:e0168170.', 'journal-title': 'PLoS ONE'}, { 'key': '491_CR46', 'doi-asserted-by': 'publisher', 'first-page': '870', 'DOI': '10.1016/j.chom.2020.05.008', 'volume': '27', 'author': 'A Park', 'year': '2020', 'unstructured': 'Park A, Iwasaki A, Type I. and type III interferons—induction, ' 'signaling, evasion, and application to combat COVID-19. Cell Host ' 'Microbe. 2020;27:870–8.', 'journal-title': 'Cell Host Microbe'}, { 'key': '491_CR47', 'doi-asserted-by': 'publisher', 'first-page': '524', 'DOI': '10.1007/s00011-008-8007-8', 'volume': '57', 'author': 'X Zhang', 'year': '2008', 'unstructured': 'Zhang X, Song Y, Ci X, et al. Ivermectin inhibits LPS-induced production ' 'of inflammatory cytokines and improves LPS-induced survival in mice. ' 'Inflamm Res. 2008;57:524–9. https://doi.org/10.1007/s00011-008-8007-8.', 'journal-title': 'Inflamm Res'}, { 'key': '491_CR48', 'doi-asserted-by': 'publisher', 'first-page': '17023', 'DOI': '10.1038/sigtrans.2017.23', 'volume': '2', 'author': 'T Liu', 'year': '2017', 'unstructured': 'Liu T, Zhang L, Joo D, Sun S-C. NF-κB signaling in inflammation. Signal ' 'Transduct Target Ther. 2017;2:17023 ' 'https://doi.org/10.1038/sigtrans.2017.23.', 'journal-title': 'Signal Transduct Target Ther'}, { 'key': '491_CR49', 'doi-asserted-by': 'publisher', 'first-page': '265', 'DOI': '10.1186/s13046-019-1251-7', 'volume': '38', 'author': 'L Jiang', 'year': '2019', 'unstructured': 'Jiang L, Wang P, Sun YJ, Wu YJ. Ivermectin reverses the drug resistance ' 'in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer ' 'Res. 2019;38:265 https://doi.org/10.1186/s13046-019-1251-7.', 'journal-title': 'J Exp Clin Cancer Res'}, { 'key': '491_CR50', 'doi-asserted-by': 'publisher', 'first-page': 'm1443', 'DOI': '10.1136/bmj.m1443', 'volume': '369', 'author': 'S Zheng', 'year': '2020', 'unstructured': 'Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, et al. Viral load dynamics ' 'and disease severity in patients infected with SARSCoV-2 in Zhejiang ' 'province, China, January-March 2020: retrospective cohort study. BMJ. ' '2020;369:m1443.', 'journal-title': 'BMJ.'}, { 'key': '491_CR51', 'doi-asserted-by': 'publisher', 'unstructured': 'Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et ' 'al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in ' 'Covid-19. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2015432.', 'DOI': '10.1056/NEJMoa2015432'}, { 'key': '491_CR52', 'doi-asserted-by': 'publisher', 'unstructured': 'Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of ' 'critical & mortal COVID-19 cases: a systematic literature review and ' 'meta-analysis. J Infect. 2020. ' 'https://doi.org/10.1016/j.jinf.2020.04.021.', 'DOI': '10.1016/j.jinf.2020.04.021'}, { 'key': '491_CR53', 'doi-asserted-by': 'publisher', 'first-page': '827', 'DOI': '10.3389/fimmu.2020.00827', 'volume': '11', 'author': 'B Diao', 'year': '2020', 'unstructured': 'Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and ' 'functional exhaustion of T cells in patients with coronavirus disease ' '2019 (COVID-19). Front Immunol. 2020;11:827.', 'journal-title': 'Front Immunol'}, { 'key': '491_CR54', 'doi-asserted-by': 'publisher', 'first-page': '718', 'DOI': '10.1126/science.abc6027', 'volume': '369', 'author': 'J Hadjadj', 'year': '2020', 'unstructured': 'Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. ' 'Impaired type I interferon activity and inflammatory responses in severe ' 'COVID-19 patients. Science. 2020;369:718–24.', 'journal-title': 'Science.'}, { 'key': '491_CR55', 'doi-asserted-by': 'publisher', 'first-page': '18', 'DOI': '10.1186/s12941-020-00362-2', 'volume': '19', 'author': 'W Chen', 'year': '2020', 'unstructured': 'Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is ' 'positively associated with the severity of COVID-19. Ann Clin Microbiol ' 'Antimicrob. 2020;19:18.', 'journal-title': 'Ann Clin Microbiol Antimicrob.'}, { 'key': '491_CR56', 'doi-asserted-by': 'publisher', 'first-page': '486', 'DOI': '10.1124/pr.119.018440', 'volume': '72', 'author': 'U Bharadwaj', 'year': '2020', 'unstructured': 'Bharadwaj U, Kasembeli MM, Robinson P, Tweardy DJ. Targeting janus ' 'kinases and signal transducer and activator of transcription 3 to treat ' 'inflammation, fibrosis, and cancer: rationale, progress, and caution. ' 'Pharm Rev. 2020;72:486–526.', 'journal-title': 'Pharm Rev'}, { 'key': '491_CR57', 'doi-asserted-by': 'publisher', 'first-page': '9812', 'DOI': '10.1128/JVI.01012-07', 'volume': '81', 'author': 'M Frieman', 'year': '2007', 'unstructured': 'Frieman M, Yount B, Heise M, Kopecky-Bromberg SA, Palese P, Baric RS. ' 'Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 ' 'function by sequestering nuclear import factors on the rough endoplasmic ' 'reticulum/golgi membrane. J Virol. 2007;81:9812–24.', 'journal-title': 'J Virol'}, { 'key': '491_CR58', 'doi-asserted-by': 'publisher', 'first-page': '1527', 'DOI': '10.3390/cancers11101527', 'volume': '11', 'author': 'J-H Kim', 'year': '2019', 'unstructured': 'Kim J-H, Choi HS, Kim S-L, Lee D-S. The PAK1-Stat3 signaling pathway ' 'activates IL-6 gene transcription and human breast cancer stem cell ' 'formation. Cancers. 2019;11:1527.', 'journal-title': 'Cancers.'}, { 'key': '491_CR59', 'doi-asserted-by': 'publisher', 'first-page': '4457', 'DOI': '10.1158/0008-5472.CAN-15-2887', 'volume': '76', 'author': 'Q Dou', 'year': '2016', 'unstructured': 'Dou Q, Chen H-N, Wang K, Yuan K, Lei Y, Li K, et al. Ivermectin induces ' 'cytostatic autophagy by blocking the PAK1/Akt axis in breast cancer. ' 'Cancer Res. 2016;76:4457–69.', 'journal-title': 'Cancer Res'}, { 'key': '491_CR60', 'doi-asserted-by': 'publisher', 'first-page': 'e14122', 'DOI': '10.15252/emmm.202114122.', 'volume': '13', 'author': 'GD De Melo', 'year': '2021', 'unstructured': 'De Melo GD, Lazarini F, Larrous F, et al. Attenuation of clinical and ' 'immunological outcomes during SARS-CoV-2 infection by ivermectin. EMBO ' 'Mol Med. 2021;13:e14122. https://doi.org/10.15252/emmm.202114122.', 'journal-title': 'EMBO Mol Med'}, { 'key': '491_CR61', 'doi-asserted-by': 'publisher', 'first-page': '281', 'DOI': '10.1085/jgp.200308986', 'volume': '123', 'author': 'A Priel', 'year': '2004', 'unstructured': 'Priel A, Silberberg SD. Mechanism of ivermectin facilitation of human ' 'P2X4 receptor channels. J Gen Physiol. 2004;123:281–93. ' 'https://doi.org/10.1085/jgp.200308986.', 'journal-title': 'J Gen Physiol.'}, { 'key': '491_CR62', 'doi-asserted-by': 'publisher', 'first-page': '291', 'DOI': '10.3389/fphar.2017.00291.', 'volume': '8', 'author': 'L Stokes', 'year': '2017', 'unstructured': 'Stokes L, Layhadi JA, Bibic L, Dhuna K, Fountain SJ. P2X4 receptor ' 'function in the nervous system and current breakthroughs in ' 'pharmacology. Front Pharm. 2017;8:291. ' 'https://doi.org/10.3389/fphar.2017.00291.', 'journal-title': 'Front Pharm'}, { 'key': '491_CR63', 'doi-asserted-by': 'publisher', 'first-page': '1159', 'DOI': '10.4049/jimmunol.1700965.', 'volume': '200', 'author': 'JA Layhadi', 'year': '2018', 'unstructured': 'Layhadi JA, Turner J, Crossman D, Fountain SJ. ATP evokes Ca2+ responses ' 'and CXCL5 secretion via P2X4 receptor activation in human ' 'monocyte-derived macrophages. J Immunol. 2018;200:1159. ' 'https://doi.org/10.4049/jimmunol.1700965.', 'journal-title': 'J Immunol.'}, { 'key': '491_CR64', 'doi-asserted-by': 'publisher', 'unstructured': 'Andersson U, Ottestad W, Tracey KJ. Extracellular HMGB1: a therapeutic ' 'target in severe pulmonary inflammation including COVID-19? Mol Med. ' '2020;26:42. https://doi.org/10.1186/s10020-020-00172-4pmid.', 'DOI': '10.1186/s10020-020-00172-4pmid'}, { 'key': '491_CR65', 'first-page': '317', 'volume': '8', 'author': 'M Juarez', 'year': '2018', 'unstructured': 'Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. The multitargeted drug ' 'ivermectin: from an antiparasitic agent to a repositioned cancer drug. ' 'Am J Cancer Res. 2018;8:317–31.', 'journal-title': 'Am J Cancer Res.'}, { 'key': '491_CR66', 'doi-asserted-by': 'publisher', 'first-page': '1015', 'DOI': '10.1016/S1473-3099(20)30293-0', 'volume': '20', 'author': 'MS Xydakis', 'year': '2020', 'unstructured': 'Xydakis MS, Dehgani-Mobaraki P, Holbrook EH, et al. Smell and taste ' 'dysfunction in patients with COVID-19. Lancet Infect Dis. ' '2020;20:1015–6. https://doi.org/10.1016/S1473-3099(20)30293-0.', 'journal-title': 'Lancet Infect Dis.'}, { 'key': '491_CR67', 'doi-asserted-by': 'publisher', 'first-page': '449', 'DOI': '10.1111/j.1472-8206.2009.00684.x', 'volume': '23', 'author': 'X Ci', 'year': '2009', 'unstructured': 'Ci X, Li H, Yu Q. Avermectin exerts anti-inflammatory effect by ' 'downregulating the nuclear transcription factor kappa-B and ' 'mitogen-activated protein kinase activation pathway. Fundam Clin Pharm. ' '2009;23:449–55.', 'journal-title': 'Fundam Clin Pharm'}, { 'key': '491_CR68', 'doi-asserted-by': 'publisher', 'first-page': '589', 'DOI': '10.1007/s00011-011-0307-8', 'volume': '60', 'author': 'S Yan', 'year': '2011', 'unstructured': 'Yan S, Ci X, Chen N. Anti-inflammatory effects of ivermectin in mouse ' 'model of allergic asthma. Inflamm Res. 2011;60:589–96.', 'journal-title': 'Inflamm Res'}, { 'key': '491_CR69', 'doi-asserted-by': 'publisher', 'unstructured': 'Zaidi AK, Dawoodi S, Pirro M, Monti M, Mobaraki PD. Key role of annexin ' 'A2 and plasmin in COVID-19 pathophysiology, clinical presentation and ' 'outcomes—a review. Ital J Prev, Diagn Ther Med. 2020;3. ' 'https://doi.org/10.30459/2020-24.', 'DOI': '10.30459/2020-24'}, { 'key': '491_CR70', 'doi-asserted-by': 'crossref', 'unstructured': 'Scheim DE. Ivermectin for COVID-19 Treatment: Clinical Response at ' 'Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated ' 'Vascular Occlusion (June 26, 2020). Available at SSRN: ' 'https://ssrn.com/abstract=3636557.', 'DOI': '10.2139/ssrn.3636557'}, { 'key': '491_CR71', 'doi-asserted-by': 'publisher', 'first-page': '259', 'DOI': '10.1038/s41569-020-0360-5.', 'volume': '17', 'author': 'YY Zheng', 'year': '2020', 'unstructured': 'Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular ' 'system. Nat Rev Cardiol. 2020;17:259–60. ' 'https://doi.org/10.1038/s41569-020-0360-5.', 'journal-title': 'Nat Rev Cardiol'}, { 'key': '491_CR72', 'doi-asserted-by': 'publisher', 'first-page': '147', 'DOI': '10.1016/j.ebiom.2017.09.022', 'volume': '24', 'author': 'H Nagai', 'year': '2017', 'unstructured': 'Nagai H, Satomi T, Abiru A, Miyamoto K, Nagasawa K, Maruyama M, et al. ' 'Antihypertrophic effects of small molecules that maintain mitochondrial ' 'ATP levels under hypoxia. EBioMedicine. 2017;24:147–58. ' 'https://doi.org/10.1016/j.ebiom.2017.09.022.', 'journal-title': 'EBioMedicine.'}], 'container-title': ['The Journal of Antibiotics'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.nature.com/articles/s41429-021-00491-6.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41429-021-00491-6', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41429-021-00491-6.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 1, 24]], 'date-time': '2022-01-24T11:04:36Z', 'timestamp': 1643022276000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 12, 21]]}, 'references-count': 72, 'journal-issue': {'issue': '2', 'published-print': {'date-parts': [[2022, 2]]}}, 'alternative-id': ['491'], 'URL': 'http://dx.doi.org/10.1038/s41429-021-00491-6', 'relation': {}, 'ISSN': ['0021-8820', '1881-1469'], 'issn-type': [{'value': '0021-8820', 'type': 'print'}, {'value': '1881-1469', 'type': 'electronic'}], 'subject': ['Drug Discovery', 'Pharmacology'], 'published': {'date-parts': [[2021, 12, 21]]}, 'assertion': [ { 'value': '20 October 2021', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '9 November 2021', 'order': 2, 'name': 'revised', 'label': 'Revised', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '10 November 2021', 'order': 3, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '21 December 2021', 'order': 4, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Compliance with ethical standards'}}, { 'value': 'The authors declare no competing interests.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of interest'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}